Xueming Qian

This inventor holds 7 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 4 EPO patents. Top assignees: Amgen Inc., Medarex Inc., E. R. Squibb Sons, Inc.. Active years: 2008-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xueming Qian. Retrieved from https://idiyas.com/inventor/xueming-qian

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 7 (Patent Applications = 1)

% Patents Active = 57.1

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 7.0

ph-index = 2

Forward Citations = 41(Granted Patents)

Location History:

Oak Park, CA (US) (2008 - 2014)
Oaks Park, CA (US) (2017)

Company Filing History:

E. R. Squibb Sons, Inc.

patents

where one patent can have more than one assignee

Years Active: 2008-2017

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9534053 - Therapeutic human anti-IL-1R1 monoclonal antibody (2017-01-03),

2. 8710203 - Therapeutic human anti-IL-1R1 monoclonal antibody (2014-04-29),

3. 8518407 - Therapeutic human anti-IL-1R1 monoclonal antibody (2013-08-27),

4. 8309092 - Wise binding agents and epitopes (2012-11-13),

5. 8236559 - Therapeutic human anti-IL-1R1 monoclonal antibody (2012-08-07),

6. 8043620 - Wise binding agents and epitopes (2011-10-25),

7. 7438910 - Therapeutic human anti-IL1-R1 monoclonal antibody (2008-10-21),

Title: Xueming Qian: Innovator in Monoclonal Antibody Development

Introduction

Xueming Qian is a prominent inventor based in Oak Park, CA (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic monoclonal antibodies. With a total of 7 patents to his name, Qian's work has the potential to impact the treatment of various diseases.

Latest Patents

Among his latest patents is the therapeutic human anti-IL-1R1 monoclonal antibody. This invention describes antibodies that interact with interleukin-1 receptor type 1 (IL-1R1). The patent outlines methods for treating IL-1 mediated diseases by administering a pharmaceutically effective amount of these antibodies. Additionally, it includes methods for detecting the amount of IL-1R1 in a sample using antibodies specific to IL-1R1.

Career Highlights

Qian has worked with notable companies in the biotechnology sector, including Amgen Inc. and Medarex Inc. His experience in these organizations has allowed him to refine his expertise in antibody development and therapeutic applications.

Collaborations

Throughout his career, Qian has collaborated with esteemed colleagues such as Brian C. Varnum and Chris Vezina. These partnerships have contributed to the advancement of his research and innovations in the field.

Conclusion

Xueming Qian's contributions to monoclonal antibody development exemplify the impact of innovation in biotechnology. His patents and collaborations highlight his commitment to advancing medical treatments and improving patient outcomes.

Profile summary based on public USPTO records.